Recent Updates
Recently added Catalysts

GridAI Technologies Corp.

GRDXFDA catalysts, PDUFA dates & pipeline intelligence
$3.3
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full GRDX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.8752W HIGH $6.93
Volume
315.11 K
Value Traded
916.02 K
Short % Float
0.52%
Days to Cover
1.0
-40.54%Week
-24.83%1 Month
-14.29%3 Month
-14.06%6 Month
-100%5 Year
-100%All Time

Cash Data

Unlock GRDX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
23.53 M
EPS (TTM)
-2.57
P/E Ratio
-
Ent. Value
23.29 M
Total Shares
7.13 M
Float Shares
5.83 M
Insiders
18.25%
Institutions
8.19%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every GRDX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

GRDX Catalyst Timeline

Dated clinical, regulatory and corporate events for GridAI Technologies Corp.

Catalyst Timeline

Dated clinical, regulatory & corporate events for GridAI Technologies Corp.

189Total events
1Upcoming
48Tier-1 (high impact)
2016 to 2027Coverage

Upcoming catalysts 1

T2Product Launch
Subscribe to view catalyst details
latiglutenase

Event history 50

▼Reverse Stock SplitCorporate
1-for-3 reverse stock split to regain Nasdaq compliance
▼Equity OfferingCorporate
Entero Therapeutics announces $3.0 million private placement of pre-funded and common warrants
◆Timing GuidancePresentation
Shareholder approval for rescission required by June 30, 2025
▲Partnership / LicenseCorporate
Signing of Rescission Agreement with ImmunogenX
●Management ChangeCorporate
Anna Skowron appointed as CFO effective March 3, 2025
◆Management ChangeCorporate
Appointment of Richard Paolone as interim CEO
◆Trial InitiationlatiglutenaseTrial
Phase 3 trial initiation expected in early 2025
celiac diseasesource ↗
◆Reverse Stock SplitCorporate
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics
▲Partnership / LicenseCorporate
Entero Therapeutics signs binding letter of intent to exclusively license QOLPOM and FotoDigm from Data Vault Holdings
◆Partnership / LicenseCorporate
Expected closing of definitive agreement for license by end of September 2024
Unlock the full GRDX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How GRDX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all GRDX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the GRDX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every GRDX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
adrulipase exocrine pancreatic insufficiency (EPI) in cystic fibrosis patientsPhase 22023-07-13the enhanced adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of adrulipaseRead MoreFirst Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase FormulationRead More
Scroll for more · summaries link to the source press release
Unlock every GRDX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock GRDX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Sawyer Jason DavidDirector, Officer (Chief Executive Officer)Grant/Award 250,000 540,000 held$0.00 06/30/2026
Unlock the full GRDX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in GRDX for Q3 2026.
Unlock every fund holding GRDX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in GRDX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see GRDX ownership
Insider and institutional ownership, quarter by quarter.

GRDX Short Interest

Shares sold short, counted twice a month.

0.52%
Short % of Float
of tradable shares sold short
30.5K
Shares Sold Short
-69.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
116.6K
Avg Daily Volume
the average used for days to cover
Unlock GRDX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock GRDX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live GRDX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock GRDX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How GRDX ranks across every disease it competes in

Competitive Position is a premium feature
See how GRDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

GRDX News

GRDX
Nov 17, 2026
GRDXGeneral

GridAI Technologies Signs Definitive Agreement to Acquire Pronghorn Resources, Establishing Major Wyoming Owned-Natural Gas and Multi-Gigawatt AI Power Infrastructure Platform Targeting Initial Power Delivery in 2027

GridAI Technologies has signed a Definitive Share Exchange Agreement to acquire Pronghorn Resources, establishing a significant energy infrastructure platform in Wyoming. The acquisition aims to support the growing demand for AI data centers, targeting 300 MW of initial power delivery by 2027. GridAI plans to leverage Pronghorn's existing assets to enhance its operational capabilities.

Read more →
GRDX
Apr 28, 2026
GRDXGeneral

GridAI Technologies Corp. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

GridAI Technologies Corp. announced that it received a notice from Nasdaq regarding its late Form 10-K filing, indicating non-compliance with requirements for continued listing. The company must submit a plan to regain compliance by June 22, 2026. If accepted, Nasdaq may grant an extension of up to 180 days. However, there are no guarantees that the plan will be accepted, raising concerns about future compliance.

Read more →
GRDX
Nov 28, 2025
GRDXGeneral

Eric Corbett 100 Long Branch Avenue Unit 21 Etobicoke, Ontario, M8W 0C1 CANADA Via Email (jason@accessalternative.com; edborkowski@gmail.com)

Eric Corbett has announced his resignation from the Board of Directors of Entero Therapeutics Inc., effective November 28, 2025. The resignation stems from fundamental disagreements with the management and the Board's policies and practices. This internal conflict may raise concerns regarding the company's governance and future strategic decisions.

Read more →
GRDX
Oct 1, 2025
GRDXGeneral

ENTERO THERAPEUTICS (NASDAQ: ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data

Entero Therapeutics, Inc. (NASDAQ: ENTO) has acquired GRID AI Corp, a grid-edge AI platform, in a strategic move to enhance its position in the burgeoning AI-driven energy infrastructure market. This acquisition is expected to allow ENTO to effectively address the rising electricity demand from data centers, projected to surge significantly in the coming years. GRID AI's platform aims to facilitate dynamic load management and improve grid reliability by integrating flexible demand from various energy resources. Following regulatory approval, GRID AI will operate as a wholly owned subsidiary of ENTO, enabling expansion into new energy capacities and market opportunities.

Read more →
GRDX
Aug 14, 2025
GRDXGeneral

Entero Therapeutics, Inc. Announces Reverse

Entero Therapeutics, Inc. has announced a 1 for 3 reverse stock split to comply with Nasdaq's listing requirements, effective August 18, 2025. This split aims to address the minimum bid price requirement and reduce the outstanding shares from approximately 4.77 million to about 1.59 million. Interim CEO Richard Paolone emphasized the importance of the Nasdaq listing for enhancing shareholder value. No fractional shares will be issued, with affected shareholders receiving cash instead.

Read more →
GRDX
Aug 11, 2025
GRDXGeneral

Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules

Entero Therapeutics, Inc. has announced a private placement of approximately $3 million with institutional investors, priced at market under Nasdaq rules. The transaction involves the sale of pre-funded and common warrants, providing significant flexibility for investors. The proceeds are intended for general corporate purposes and working capital. The expected closing date for the transaction is August 11, 2025, pending customary closing conditions. This offering reflects Entero's ongoing efforts to support its development of targeted therapies for gastrointestinal diseases.

Read more →
GRDX
Mar 24, 2025
GRDXGeneral

Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC.

Entero Therapeutics announced the signing of a rescission agreement with ImmunogenX to unwind a previously closed business combination. This decision, made after an internal review, is viewed as a strategic move to strengthen Entero's balance sheet and focus on long-term success. Furthermore, the company appointed Anna Skowron as its new Chief Financial Officer, bringing valuable experience in financial reporting and corporate governance. However, the agreement is contingent on obtaining shareholder approval by June 30, 2025.

Read more →
GRDX
Feb 14, 2025
GRDXGeneral

Therapeutics Appoints Richard Paolone as CEO

Entero Therapeutics, Inc. has appointed Richard Paolone as interim CEO, bringing a wealth of experience in corporate finance, securities law, and mergers and acquisitions. Paolone is expected to leverage his expertise to guide the company in a competitive market. Entero specializes in developing targeted therapies for gastrointestinal diseases, with drugs in its pipeline aimed at significant unmet medical needs.

Read more →
GRDX
Nov 13, 2024
GRDXGeneral

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company Proposed merger to create N

Entero Therapeutics has announced a proposed reverse merger with Journey Therapeutics, a clinical-stage biopharmaceutical company specializing in nano-immunoconjugates for cancer treatment. Following the merger, shareholders of Journey will control 99% of the combined entity, which will operate under the Journey Therapeutics name. The merger aims to enhance Entero's existing clinical assets while advancing Journey's novel therapies targeting difficult cancers. However, the merger is subject to various conditions, including financing and regulatory approvals.

Read more →
GRDX
Sep 10, 2024
GRDXGeneral

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings Entero Therapeutics to integrate applications in plann

Entero Therapeutics has signed a Letter of Intent with Data Vault Holdings to license and commercialize innovative clinical trial management technologies, including QOLPOM and FotoDigm. This partnership aims to enhance compliance in clinical trials, starting with a Phase 3 trial for latiglutenase in celiac disease. The transaction hinges on securing a strategic investment which would provide significant capital and support for technology development. Should the technologies prove effective in trials, they could lead to broader applications in the pharmaceutical sector.

Read more →
GRDX
Aug 23, 2024
GRDXGeneral

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced it received a notification from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter that ended June 30, 2024. The company has until October 21, 2024, to submit a compliance plan to Nasdaq, which may extend the deadline for filing up to February 17, 2025, if approved. Alongside this, Entero Therapeutics is in the process of retaining a new independent registered public accounting firm after its previous firm resigned. However, there remains uncertainty regarding the company's ability to meet Nasdaq's compliance criteria.

Read more →
GRDX
Jul 31, 2024
GRDXPhases

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Entero Therapeutics' Chairman and CEO James Sapirstein provided a business update focusing on the development of latiglutenase, a treatment for celiac disease. The company aims to advance latiglutenase into a pivotal Phase 3 trial by 2025 and is adjusting its trial design based on previous discussions with the FDA. Entero has secured $1.9 million in financing and has streamlined its operations to support this process. Their approach reflects a strong commitment to meeting the treatment needs for patients with celiac disease.

Read more →
GRDX
Jul 11, 2024
GRDXGeneral

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Entero Therapeutics, Inc. announced the exercise of existing warrants and issuance of new ones in a private placement, resulting in approximately $1.9 million in gross proceeds. The existing warrants, totaling 1,762,674 shares, will be exercised at a reduced price of $1.09 per share. In exchange, the holders will receive new warrants for an additional 3,525,348 shares at the same exercise price, pending stockholder approval. This strategy aims to strengthen Entero's financial capabilities to further develop its innovative therapies for gastrointestinal diseases.

Read more →
GRDX
May 17, 2024
GRDXPhases

First Wave BioPharma Changes Name to Entero Therapeutics Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset - latiglutenase for the treatment of celiac disease New Nasdaq new ticker s

First Wave BioPharma has changed its name to Entero Therapeutics as it prepares for a Phase 3 clinical trial of its lead asset, latiglutenase, aimed at treating celiac disease. The rebranding reflects the company's commitment to addressing unmet gastrointestinal health needs. The new ticker symbol ENTO will be effective on May 17, 2024. Additionally, Entero is collaborating with Celiac Journey to promote awareness about celiac disease during Celiac Awareness Month. The success of the Phase 3 trial and the integration of ImmunogenX assets presents both opportunities and challenges for Entero's future.

Read more →
GRDX
May 10, 2024
GRDXGeneral

First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market

First Wave BioPharma, Inc. has announced a definitive securities purchase agreement to raise approximately $1.1 million through the sale of 366,000 shares priced at $2.95 each. Additionally, the agreement includes warrants for purchasing another 732,000 shares at an exercise price of $2.70. The proceeds from this offering will be utilized for general corporate purposes and working capital. Roth Capital Partners is acting as the exclusive placement agent for this transaction, which is expected to close around May 14, 2024.

Read more →
GRDX
Mar 18, 2024
GRDXConferences/Events

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference Poster presentations to highlight new quantitative and serologic diagn

First Wave BioPharma announced that two research abstracts on celiac disease have been accepted for presentation at the 2024 Digestive Disease Week Conference. These presentations will focus on new diagnostic methods, including the VCIEL scale for measuring mucosal health and the dynamics of serologic changes in patients. The findings are expected to contribute significantly to the understanding and management of celiac disease, highlighting advancements in gastroenterology. The conference will take place from May 18-21, 2024, in Washington, D.C.

Read more →
GRDX
Mar 14, 2024
GRDXPhases

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline Latiglutenase is a potentially first-in-class oral biot

First Wave BioPharma has successfully completed its acquisition of ImmunogenX, integrating latiglutenase into its pipeline as a Phase 3-ready treatment for celiac disease. The merger aims to enhance First Wave's capabilities in developing targeted therapies for gastrointestinal diseases. Latiglutenase has shown promising results in earlier trials and is expected to enter Phase 3 trials in early 2025, following FDA approval of its clinical development plan. The company plans to license commercial rights for the drug to a global pharmaceutical partner and seeks additional financing to support its development efforts.

Read more →
GRDX
Mar 4, 2024
GRDXGeneral

First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering

First Wave BioPharma, Inc. has announced a registered direct offering, aiming to raise approximately $4.0 million by selling 525,625 shares of common stock at a price of $7.61 per share. Alongside this, the company will issue warrants to purchase up to the same number of shares at an exercise price of $7.48 per share. The gross proceeds from the offering are designated for working capital and general corporate needs. Roth Capital Partners is acting as the exclusive placement agent, with the closing expected around March 6, 2024, pending customary conditions.

Read more →
GRDX
Jan 4, 2024
GRDXPhases

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024 Multiple clinical and development milestones anticipated in 2024, including initiation of Phase

First Wave BioPharma's Chairman and CEO, James Sapirstein, issued a letter to shareholders outlining recent achievements and the company's 2024 outlook. Key highlights include a potential merger with ImmunogenX, which would provide access to the Phase 3-ready latiglutenase for celiac disease. The company anticipates major clinical and development milestones in 2024, alongside strategic investments for commercial rights. First Wave aims to strengthen its late-stage clinical pipeline focused on gastrointestinal disorders.

Read more →
GRDX
Dec 27, 2023
GRDXPhases

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 L

First Wave BioPharma has announced its intention to streamline its clinical pipeline by entering a non-binding term sheet for the sale of its Niclosamide program, which targets inflammatory bowel diseases. This strategic decision will allow the company to focus its efforts on advancing three key late-stage clinical programs, including a Phase 3-ready treatment for celiac disease and other GI-focused therapies. The transaction is expected to close in the first half of 2024, pending various regulatory approvals and financing conditions. The sale aims to infuse the company with additional capital to bolster its development resources.

Read more →

About GridAI Technologies Corp.

Boca Raton, FL 2 employees enterothera.com
Headquarters433 PLAZA REAL, BOCA RATON, FL
BIOPHARMAWATCH ELITE
Trade the next GRDX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime